hairlossDutasteride is a prescription pill that blocks both forms of the enzyme that turns testosterone into DHT, the hormone behind male pattern hair loss. In randomized trials it grew more hair than finasteride over six months, and a 2022 network meta-analysis ranked it first for hair count at 24 weeks. It is approved for hair loss in South Korea and Japan but, as of November 2026, is still prescribed off-label for this use in the United States, and it carries label rules every user should know.
Most write-ups stop at the headline "stronger than finasteride." This one goes a level deeper: each major study is laid out below with its size, length, funding and blind spots, so you can judge how much weight that headline can carry.
How dutasteride differs from finasteride
Both drugs are 5-alpha-reductase inhibitors. Finasteride blocks the type II enzyme; dutasteride blocks type I and type II. In men with prostate enlargement, dutasteride lowered blood DHT by about 98% compared with about 71% for finasteride (as summarized by Choi et al., 2022). If DHT is new to you, our explainer on DHT and hair loss covers the basics.
The other big difference is how long the drug stays in the body. Finasteride's half-life is a matter of hours; dutasteride's is roughly five weeks. That slow washout shapes side effects, blood donation and family planning, as covered below.
The evidence, study by study
| Study | Who and how many | Length | Main finding | Watch-outs |
|---|---|---|---|---|
| Olsen et al., JAAD 2006 | 416 men aged 21 to 45 | 24 weeks | Hair gains rose with dose; 2.5 mg outperformed finasteride 5 mg | Dose-finding trial; finasteride arm used the prostate dose, not the 1 mg hair dose |
| Eun et al., JAAD 2010 | 153 Korean men aged 18 to 49 with crown thinning | 6 months | Hair count rose 12.2 hairs/cm² vs 4.7 on placebo | Placebo comparison only; one country; manufacturer-supported |
| Gubelin Harcha et al., JAAD 2014 | 917 men aged 20 to 50 across five arms | 24 weeks | 0.5 mg beat finasteride 1 mg and placebo for hair count and hair width | Manufacturer-funded; six months only |
| Gupta et al., JAMA Dermatology 2022 | Network meta-analysis of 23 studies in men | 24 and 48 weeks | 0.5 mg ranked first for total hair count at 24 weeks, about 7 hairs/cm² ahead of finasteride 1 mg | Largely indirect comparisons; no 48-week dutasteride data |
| Choi et al., Annals of Dermatology 2022 | 600 Korean men (295 dutasteride, 305 finasteride) | At least 3 years (average 3.4) | On standard doses, 86% of dutasteride users improved a hair-loss grade vs 46% on finasteride | Retrospective chart review; manufacturer-funded; the dutasteride group used more minoxidil |
What these studies did show
Across different countries and designs, the direction is consistent. At 0.5 mg a day, dutasteride produced more hair than placebo and, in the largest head-to-head trial, more than the standard 1 mg finasteride dose. In that 917-man trial, hair count and hair thickness climbed step by step as the dose went from 0.02 mg to 0.1 mg to 0.5 mg, the kind of dose-response pattern that makes a genuine drug effect more believable. The meta-analysis put the advantage over finasteride 1 mg at roughly 7 hairs per square centimeter after six months, with a 95% confidence interval of about 5 to 9.
What they did not show
- Long-term randomized data. The controlled trials stop at about six months. The three-year evidence comes from a chart review, which cannot rule out that the two groups differed in ways their charts did not capture. In that review, dutasteride users were older, had more advanced loss at the start and were more likely to also use minoxidil.
- Independent replication at scale. Most of the key trials were funded by the drug's original manufacturer. That does not make them wrong, but the independent evidence base is thinner than it is for finasteride.
- Rare side effects. Trials of a few hundred men over six months are too small and too short to measure uncommon problems reliably.
- Women. All of these trials enrolled men. Use in women is off-label, rests on small studies, and is never appropriate during pregnancy or when pregnancy is possible. Our guide to female hair loss covers the better-studied options.
Side effects: what the trials and the label say
In the 917-man trial, the number and severity of side effects were similar across the dutasteride, finasteride and placebo groups. In the three-year Korean review, sexual side effects, mostly lower libido, were recorded in 1.6% of dutasteride users and 1.1% of finasteride users on standard doses. The authors caution that dermatologists may not record sexual problems as thoroughly as clinical trials do, so real-world rates could be higher. Side effects reported with this drug class include lower sex drive, erection or ejaculation changes, and breast tenderness or enlargement; mood changes have also been reported and should be raised with the prescriber promptly.
The US prescribing information, written for prostate enlargement, adds points that apply to anyone taking the drug (FDA label via DailyMed):
- PSA drops by about half. Dutasteride lowers prostate-specific antigen, a prostate cancer screening test, by roughly 50% within 3 to 6 months. Tell whoever orders your PSA that you take it, because the result has to be read differently.
- High-grade prostate cancer warning. The label states this drug class may increase the risk of high-grade prostate cancer, a finding from large prevention trials in older men.
- No blood donation for six months. Men should wait at least six months after the last dose before donating, so the drug never reaches a pregnant transfusion recipient.
- Pregnant women should not handle leaking capsules. The drug can be absorbed through the skin and may affect the development of a male fetus.
- Semen changes. In healthy men, a year of treatment lowered average sperm count, semen volume and motility, and sperm count had not fully recovered 24 weeks after stopping. Anyone planning a family soon should discuss this first.
Why the long half-life matters in practice
Because dutasteride lingers for weeks, its effects do not switch off quickly. That cuts both ways. A missed dose matters little, but side effects can also take longer to fade after stopping, and the six-month blood-donation wait reflects how long traces remain. Stopping is not a reset button for the hair either: as with finasteride, hair gained on treatment is expected to recede gradually once the drug is stopped, because the scalp's inherited sensitivity to DHT has not changed.
Where dutasteride fits
In the United States, the only medicines approved for pattern hair loss are topical minoxidil and oral finasteride 1 mg, so they remain the usual first steps. Japan's dermatology guideline goes further and lists dutasteride alongside finasteride as a first-line option for men. In US practice, dutasteride tends to come up when finasteride has not done enough after a fair trial of a year or so, or when a man and his doctor decide the stronger DHT reduction is worth an off-label prescription. It is often combined with minoxidil, which works by a different route; see our minoxidil FAQ. Men heading toward surgery should know that medication cannot replace lost follicles, but it may help protect the hair around a hair transplant.
Questions to settle with your doctor before starting
- Is this definitely androgenetic alopecia, and where does it sit on the Norwood scale?
- Should I have a baseline PSA, given my age and family history?
- Am I planning to have children in the next year or two?
- Have I had depression or other mood problems in the past?
- How will we measure progress: standardized photos at six and twelve months?
Dutasteride is a prescription medicine that a doctor must prescribe and monitor. If you are weighing it against other options, you can ask Hairloss.org a question, browse more research in Hairloss Labs, or find a specialist through our surgeon directory.